RSNA 2023: Unveiling icometrix' AI-Driven Neuroimaging Revolution for Optimal Patient Care

Nov 22, 2023

The culmination of the year’s radiology events, the RSNA conference in Chicago presents an opportune moment for collaboration, reflection, and anticipation. Artificial Intelligence (AI) will be an important topic at RSNA again, as many AI solutions are increasingly adopted and becoming the standard of care. In addition, as we hear from our partners, customers, and scientific societies, neuroradiology will be at the center stage, given the changes in the field of neurology and the increasing need for brain MRI and CT scans. icometrix is at the center and the forefront of this dynamic landscape, with our FDA-cleared icobrain portfolio impacting radiological reading and patient care at a rapid pace. In our relentless pursuit of excellence, we are thrilled to share how our innovative solutions support the healthcare challenges of today and tomorrow.

Although AI was first introduced in the mid-20th century, rapid enhancement in data availability and computational power allowed AI solutions to start impacting care around 2010. Today, it is energizing to see how healthcare has advanced beyond perceiving AI as just another gimmick or a black-box tool that could replace radiologists, towards embracing AI-fueled applications in the day-to-day clinical practice to advance workflow and care. 

Over the years, the icometrix team has worked hard to develop and transform the icobrain portfolio to its current state. From the start, we have embraced the huge opportunities of AI, not as the end goal, but as a means to impact workflows and patient care. The independent Mendelsohn et al., 2022 publication recognized our efforts, demonstrating our leading position in the field of multiple sclerosis (MS) and the approach of scientifically validating the technology at the technical and workflow, the clinical-impact, as well as the societal-impact and cost-saving level.

Figure by Mendelsohn et al., 2022. The distribution of publications included in the review for each company identified. The vendors are listed chronologically according to date of their first FDA/CE approval.

This strong focus on science, validation, quality and regulatory, and validation again, doesn’t only provide our customers the peace of mind that the icobrain AI is a trusted partner. Based on the provided icometrix evidence linked to the clinical need, it also led to the introduction of new CPT III codes in the US (0865T and 0866T), which will become active in January 2024, and will further support the implementation of icobrain as a standard of care nationwide. Hence, it is exciting to see how the icobrain reports impact the radiological workflow, clinical decision-making, and patient care at scale. As an example, we assist radiologists and neurologists to assess subtle disease activity, as measured by new/enlarging lesions and brain atrophy, in MS. Measuring this disease activity early is crucial to optimize treatment paradigms, as suggested by the clinical guidelines, which impacts long-term outcomes significantly. This interaction between biomarker-driven measures of disease activity and progression and the availability of treatment options finally drives us towards precision medicine in neurology.

MS is a great example of moving towards data-driven decision making in neurology, optimizing treatment decisions, and entering the realm of precision medicine, as has been done in oncology, diabetes, etc. In Alzheimer’s disease (AD), many biomarkers have been validated, which can assist in the (timely) diagnosis and treatment monitoring. With the new treatments becoming available in AD, the era of precision medicine and precision care is starting today. And again, as in MS, brain MRI scans will play a central role in monitoring disease activity and safety when Alzheimer’s disease patients are on treatment. 

In addition to the recent redesign of our icobrain dm report to support the early diagnosis and assess eligibility for these new treatments, we are excited to share our unique developments that assist radiologists in the analysis of amyloid-related imaging abnormalities (ARIA). icobrain aria (FDA pending) has been developed based on a large clinical trial data base of patients being treated with amyloid-targeting therapies, which were recently approved by the FDA.  A large and unique reader study, which was presented at the last CTAD conference in October 2023, demonstrated a significant impact of icobrain aria on the ARIA detection and analysis of the severity. At RSNA, we will share further insights about the impact of icobrain aria on the reading of MRI safety scans and on the resulting clinical decisions and care. Meet us at the Learning Center Theater at RSNA November 29 (10:00 - 10:30 AM)!

We are proud to make a difference for patients by tackling the challenges within the healthcare system of today and tomorrow. Meet our team at booth #4914 during the vibrant RSNA conference!Join us at the Learning Center Theater at RSNA November 29 (10:00 - 10:30 AM) - Click here to add the event to your calendar!